CLASS ACTION UPDATE for PEN, REGI and ATNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / March 16, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
PEN Shareholders Click Here: https://www.zlk.com/pslra-1/penumbra-inc-information-request-form?prid=13717&wire=1
REGI Shareholders Click Here: https://www.zlk.com/pslra-1/renewable-energy-group-inc-loss-submission-form?prid=13717&wire=1
ATNX Shareholders Click Here: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=13717&wire=1
* ADDITIONAL INFORMATION BELOW *
Penumbra, Inc. (NYSE:PEN)
PEN Lawsuit on behalf of: investors who purchased August 3, 2020 - December 15, 2020
Lead Plaintiff Deadline : March 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/penumbra-inc-information-request-form?prid=13717&wire=1
According to the filed complaint, during the class period, Penumbra, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.
Renewable Energy Group, Inc. (NASDAQ:REGI)
REGI Lawsuit on behalf of: investors who purchased May 3, 2018 - February 25, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/renewable-energy-group-inc-loss-submission-form?prid=13717&wire=1
According to the filed complaint, during the class period, Renewable Energy Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to failures in the diesel additive system, petroleum diesel was not periodically added to certain loads by the Company and was instead added by the Company's customers; (2) as a result, Renewable Energy was not the proper claimant for certain BTC payments on biodiesel it sold between January 1, 2017 and September 30, 2020; (3) as a result, Renewable Energy's revenue and net income were overstated for certain periods; (4) there was a material weakness in the Company's internal control over financial reporting related to the purchase and use of the petroleum diesel gallons when blending with biodiesel; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Athenex, Inc. (NASDAQ:ATNX)
ATNX Lawsuit on behalf of: investors who purchased August 7, 2019 - February 26, 2021
Lead Plaintiff Deadline : May 3, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=13717&wire=1
According to the filed complaint, during the class period, Athenex, Inc. made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) that the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/635841/CLASS-ACTION-UPDATE-for-PEN-REGI-and-ATNX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
